Skip to content

effect of Darchini in Premenstrual syndrome

Therapeutic Evaluation of Darchini (Cinnamomum zeylanicum) in Premenstrual Syndrome: A Randomized Single Blind Placebo Controlled Trial - PMS

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/102779
Enrollment
40
Registered
2026-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N943- Premenstrual tension syndrome

Interventions

Intervention1: Safoof of Darchini (Cinnamomum zeylanicum): Two Capsules Each Containing 500 mg of Safoof Darchini Filled in Capsules, Orally Twice a Day for 15 Days Prior to the Expected Date of Menst

Sponsors

State Takmeeluttib College And Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Married and unmarried women above 18 years with normal menstrual cycle Clinically diagnosed cases of PMS (According to PMTS Scales)

Exclusion criteria

Exclusion criteria: Irregular menstrual cycle Pregnant and lactating women Use of hormone replacement therapy or oral contraceptives, Known systemic or metabolic disease, Patient on antipsychotic therapy Allergic to cinnamon Patient with history of acid peptic disorder

Design outcomes

Primary

MeasureTime frame
Improvement in Symptoms assessed by PMTS-OR & PMTS-VAS in treatment cycle.Timepoint: 60 days

Secondary

MeasureTime frame
Persistence of improved symptoms in post treatment cycle Adverse effects Use of rescue medication Timepoint: 60 days

Countries

India

Contacts

Public ContactDr Aiman Kulsum Nasim

State Takmeeluttib College and Hospital

dr_maniramsingh@rediffmail.com8423307654

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026